Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, crossover study comparing the Bioavailability of single doses of 186 µg and 372 µg of OPTINOSE FLUTICASONE (intranasal spray) with 400 µg of Flonase (Fluticasone Propionate) Nasal Spray (Part 1)

Trial Profile

Randomised, crossover study comparing the Bioavailability of single doses of 186 µg and 372 µg of OPTINOSE FLUTICASONE (intranasal spray) with 400 µg of Flonase (Fluticasone Propionate) Nasal Spray (Part 1)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors OptiNose
  • Most Recent Events

    • 12 Nov 2019 Results of Part I and II studies assessing pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance published in the Clinical Therapeutics
    • 04 Apr 2017 New trial record
    • 06 Mar 2017 Results of Part I and Part II studies assessing bioavailability of FLU-EDS, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top